Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Cowboys’ Scandrick Gets Four-Game NFL Ban After Failed Drug Test

Aug. 12 (Bloomberg) -- Dallas Cowboys cornerback Orlando Scandrick has been suspended without pay for the first four games of the regular season after violating the National Football League’s policy on performance-enhancing substances.

Scandrick, a six-year NFL veteran who started 15 of 16 games for the Cowboys last season, said in a statement he unknowingly took a banned drug while on vacation in Mexico. ESPN said Scandrick, 27, tested positive for MDMA, or ecstasy, which has hallucinogenic qualities and can suppress inhibition, citing unidentified people familiar with the situation.

“Failing a drug test is far out of my character,” Scandrick said in a statement, in which he apologized to his family, teammates, coaches and fans. “I take full responsibility for what goes in my body and more importantly the embarrassment of a failed drug test.”

Scandrick, who had two interceptions last season, will miss the Cowboys’ games against the San Francisco 49ers, Tennessee Titans, St. Louis Rams and New Orleans Saints. He’ll be eligible to return to the team’s active roster on Sept. 29, ahead of an Oct. 5 game against the Houston Texans.

To contact the reporter on this story: Erik Matuszewski in New York at matuszewski@bloomberg.net

To contact the editors responsible for this story: Michael Sillup at msillup@bloomberg.net Jay Beberman

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.